Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-center, Phase I Clinical Study to Evaluate the Safety and Tolerability of Multiple Antigen Stimulating Cellular Therapy-I (MASCT-I) in Patients With Advanced Solid Tumor, and to Preliminarily Evaluate the Anti-tumor Efficacy of MASCT-I Alone, in Combination With Chemical Drugs, and in Combination With PD1 Antibody

NCT03034304 is registered in ClinicalTrials.gov with HRYZ Biotech Co. as lead sponsor.

NCT NCT03034304
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03034304 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-center, Phase I Clinical Study to Evaluate the Safety and Tolerability of Multiple Antigen Stimulating Cellular Therapy-I (MASCT-I) in Patients With Advanced Solid Tumor, and to Preliminarily Evaluate the Anti-tumor Efficacy of MASCT-I Alone, in Combination With Chemical Drugs, and in Combination With PD1 Antibody
Lead sponsor
HRYZ Biotech Co.
Phase
Phase 1
Overall status
Terminated
Start date
February 22, 2017
Completion date
November 13, 2023
Enrollment
105 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors